Leqembi Market Report 2026

Leqembi Market Overview

• The Leqembi market growth in the historic period has been driven by increasing prevalence of alzheimer’s disease, advancements in monoclonal antibody research • Market expansion is supported by increasing investments in neurodegenerative disease research, rising adoption of early diagnostic tools • Growth Driver: Rising Alzheimer's Prevalence Fuels Growth Of The Leqembi Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Leqembi Market?

Leqembi (generic name: lecanemab) is a prescription medication used for the treatment of alzheimer’s disease. Leqembi is designed to treat progressive neurodegenerative disorder that causes memory loss, cognitive decline, and impaired daily functioning. The drug specifically targets the underlying pathology of alzheimer’s by reducing amyloid-beta plaques in the brain, which are believed to contribute to the disease's progression. The main types of leqembi formulations are injectable formulations (intravenous) and ready-to-use solutions. The intravenous injectable formulation delivers medication directly into the bloodstream for rapid absorption and precise dosing and is typically used for patients with advanced conditions or those requiring consistent medication levels. It is applicable for several indications, such as treatment of Alzheimer’s disease, management of mild cognitive impairment, and others for various patient demographics, including adult patients, geriatric patients, and patients with early-stage Alzheimer’s disease. It is distributed by several distribution channels, such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and used by various end users, including hospitals, neurology clinics, memory care facilities, and home healthcare providers.

What Is The Leqembi Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising adoption of early diagnostic tools, expansion of personalized alzheimer’s treatment protocols, growing focus on slowing disease progression, increased payer coverage for innovative therapies. Major trends in the forecast period include increasing adoption of amyloid-targeting therapies, rising focus on early-stage alzheimer’s intervention, growing demand for disease-modifying neurodegenerative treatments, expansion of biomarker-guided patient selection, enhanced monitoring of cognitive outcomes.

Global Leqembi Market Segmentation

1) By Formulation: Injectable Formulation (Intravenous), Ready-To-Use Solutions 2) By Indication: Treatment Of Alzheimer’s Disease, Management Of Mild Cognitive Impairment, Other Neurodegenerative Disorders 3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With Early-Stage Alzheimer’s Disease 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Neurology Clinics, Memory Care Facilities, Home Healthcare Providers

What Are The Drivers Of The Leqembi Market?

The increasing prevalence of alzheimer's disease is gaining traction in leqembi market going forward. Alzheimer's disease is a degenerative brain disorder that progressively affects memory, cognition, and behavior, disrupting daily life. Alzheimer's disease is a complex condition with several factors contributing to its development, including genetic, lifestyle, and environmental influences. Leqembi reduces beta-amyloid plaques in the brain, helping slow cognitive decline in early Alzheimer's disease by targeting plaques and protecting memory and cognitive functions. For instance, in September 2024, according to the European Brain Council, a Belgium-based international health organization, approximately 7 million people in Europe currently live with Alzheimer's disease, a number expected to double to 14 million by 2030 due to an aging population, making it a significant global public health challenge. Therefore, the increasing prevalence of alzheimer's disease is driving the growth of the leqembi industry. The key company operating in the leqembi market is focused on developing advanced intravenous (IV) maintenance dosing formulations to reduce the frequency of administration for individuals with Alzheimer's disease. An intravenous (IV) maintenance dosing formulation involves delivering a consistent or recurring dose of medication directly into the bloodstream to sustain therapeutic levels over a prolonged duration. For instance, in June 2024, Eisai Co., Ltd., a Japan-based pharmaceutical company, and Biogen Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental biologics license application (sBLA) for a monthly LEQEMBI intravenous (IV) maintenance dosing regimen. This treatment targets toxic amyloid proteins, specifically protofibrils, which are believed to contribute to cognitive decline in Alzheimer's disease (AD). LEQEMBI has shown clinical and biomarker benefits in extending treatment efficacy, potentially reducing neuronal damage, and improving long-term patient outcomes.

Key Players In The Global Leqembi Market

Major companies operating in the leqembi market are Eisai Co. Ltd.

What Are Latest Mergers And Acquisitions In The Leqembi Market?

In November 2024, Biogen Inc., a US-based biotechnology company, partnered with Eisai Co., Ltd. The collaboration is focused on developing and commercializing Alzheimer's disease treatments, with a particular emphasis on Leqembi (lecanemab) for patients in the early stages of the disease. Eisai Co. Ltd. is a Japan-based pharmaceutical company that manufactures leqembi.

Regional Insights

North America was the largest region in the leqembi market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Leqembi Market?

The leqembi market consists of sales of oral tablets or capsules, subcutaneous injections, and transdermal patches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Leqembi Market Report 2026?

The leqembi market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the leqembi industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.